Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.
Summary: In this interview, Catalent expert Judith Jones discusses the challenges associated with advancing a repositioned drug and how to overcome them to achieve strategic success.
Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.
Summary: In this webinar, experts discuss new cell line development methodologies and how the use of novel technologies can enable simplified process intensification for cell culture harvest and downstream processes.
Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.
